The OneXpress solution accelerates a programme’s transition from early phase development to commercial-ready manufacturing by leveraging Catalent’s phase-appropriate scale, technologies, extensive oral dose form network and expertise to reduce risk, complexity and cost between phases.
By eliminating the need to transition projects between multiple service providers, the duplication of tasks can be avoided, API consumption can be reduced and drug products can reach patients faster.
With a tightly integrated global network and streamlined programme management, the OneXpress solution combines the expertise at Catalent’s early phase drug development centres in Nottingham, UK, Somerset, New Jersey, and San Diego in the US with the proven track record of Catalent’s oral solid commercial manufacturing facilities.
“The oral drug development path is lengthy and complex, so to maximise speed and flexibility and reduce costs, innovators need to select development partners with the expertise and capabilities that are best suited for each stage in their development cycle,” commented Jeremie Trochu, Vice President, Oral and Specialty Delivery at Catalent.
“Our teams have collaborated across sites to harmonise equipment, materials and protocols, to ensure accelerated and seamless scale up from first-in-human trials to commercial launch. We successfully transferred more than a dozen OneXpress projects in the last year alone.”
The OneXpress solution adds to Catalent’s range of integrated offerings, including OneBio Suite, OptiForm Solution Suite and OptiForm Total Supply, which can accelerate the development and scale-up of promising compounds into successful treatments.
